The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.

Injectable weight loss drugs are popular right now but can be hard to get because they are in short supply or too expensive without insurance. The result is that some people are skipping the doctor's office and reaching out to potentially unreliable sources such as unlicensed online pharmacies or telehealth sites,

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having its dreams dashed amid new trials showing that the drugs cause most people to yak. As the Financial Times reports,

Novo Nordisk's weight loss drug, Saxenda, helped children ages six to 11 reduce their body mass index in a recent trial.

In July, the U.S. Food and Drug Administration warned that people are overdosing on compounded semaglutide injectable products.

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise.

In a society that has so many people who are overweight, it is understandable there’s such a craze for new drugs that are helping people to lose weight. Drugs like Ozempic and Wegovy were developed for people with diabetes but have proven to be great resources for losing weight.

F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.